Q-omics provides the consensus-scored ADH5P3 profile across patient tissues and cancer cell-line models. ADH5P3 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, ADH5P3 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, ADH5P3 RNA expression shows 7,482 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight STAD, KIRC, and TGCT as cancer lineages where ADH5P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADH5P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADH5P3 survival associations across molecular data types. ADH5P3 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADH5P3 RNA expression–survival associations across cancer types. High ADH5P3 expression shows unfavorable associations in STAD, LGG, BLCA and CHOL, but favorable associations in KIRP and READ. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for ADH5P3 RNA expression.
This table summarizes ADH5P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ADH5P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADH5P3 shows lower tumor expression in KIRC, KIRP, UCEC, BRCA and KICH and higher tumor expression in HNSC. The KIRC box plot shows higher ADH5P3 RNA expression in normal versus tumor tissue (log2 FC = −0.032, t-test p = .028).
This table shows molecular features associated with ADH5P3 in patient tissues and cancer cell lines. In patient samples, ADH5P3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
